Mesothelioma Clinical Trial Opens with High Expectations
Newly diagnosed mesothelioma patients around the world have begun enrolling in a much-anticipated, phase III clinical trial involving an immunotherapy drug combination with groundbreaking potential.
The trial, designed as first-line therapy for unresectable pleural mesothelioma, will measure the effectiveness of nivolumab (Opdivo) and ipilimumab (Yervoy) against standard-of-care chemotherapy.
A presentation this month at the 2017 American Society of Clinical Oncology (ASCO) annual meeting sparked high expectations for the trial, detailing early, impressive effectiveness involving the two drugs in second-line and third-line treatments.
Pharmaceutical giant Bristol-Myers Squibb is sponsoring the latest clinical trial that will include investigational sites in 20 countries and 17 cancer centers across the U.S., including:
Moffitt Cancer Center in Tampa, Florida
WVU Mary Babb Randolph Cancer Center in Morgantown, West Virginia
University of Chicago Cancer Center
Abramson Cancer Center in Philadelphia
Mayo Clinic in Rochester, Minnesota
Smilow Cancer Hospital in New Haven, Connecticut
Cleveland Clinic Cancer Center
“We’re ultimately hoping [with this trial] to forge a new standard of care for mesothelioma,” Dr. Patrick Ma, lead investigator at WVU Cancer Center, told Asbestos.com. “Yes, the expectations for this trial are high.”
Previous Results Are Impressive
The ASCO presentation in Chicago was based on a multi-center phase II trial in France that included 125 pat...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center American Society of Clinical Oncology Bristol-Myers Squibb cancer immunotherapy research cisplatin for mesothelioma Cleveland Clinic Cancer Center CRS-207 disease control rate Dr. Arnaud Scherpereel Dr. Patrick Ma Source Type: news
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Environmental Health | Hospitals | Immunotherapy | Learning | Listeria | Lung Cancer | Merck | Mesothelioma | Non-Small Cell Lung Cancer | Occupational Health | Rare Diseases | Study | Universities & Medical Training | Yervoy